Strain specific phage treatment for Staphylococcus aureus infection is influenced by host immunity and site of infection

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Pincus, Nathan B ^a   Reckhow, Jensen D ^a   Saleem, Danial ^a   Jammeh, Momodou L ^a   Datta, Sandip K ^a   Myles, Ian A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIABILITY; BACTERIOPHAGE; BACTERIOPHAGE SATA 8505; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KERATINOCYTE; MOLECULAR THERAPY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGE THERAPY; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THERAPY EFFECT; ANIMAL; BACTERIOLYSIS; DISEASE MODEL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL VIABILITY; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS; VIROLOGY;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; BACTERIOLYSIS; BACTERIOPHAGES; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; KERATINOCYTES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84928789019     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124280     Document Type: Article

References (52)

1. Klem J, Dömötör D, Schneider G, Kovács T, Tóth A, Rákhely G (2013) Bacteriophage therapy against Staphylococci. Acta Microbiologica et Immunologica Hungarica 60: 411-422. doi: 10.1556/AMicr.60.2013.4.3 PMID: 24292085
2. (2014) Antimicrobial resistance: global report on surveillance. World Health Organization.
3. Alanis AJ (2005) Resistance to antibiotics: are we in the post-antibiotic era? Archives of Medical Research 36: 697-705. PMID: 16216651
4. Myles IA, Datta SK (2012) Staphylococcus aureus: an introduction. Semin Immunopathol 34: 181-184. doi: 10.1007/s00281-011-0301-9 PMID: 22282052
5. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, et al. (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. Journal of Infection and Chemotherapy 11: 211-219. PMID: 16258815
6. Sulakvelidze A, Alavidze Z, Morris JG (2001) Bacteriophage Therapy. Antimicrobial Agents and Chemotherapy 45: 649-659. PMID: 11181338
7. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. Journal of Pharmacy and Pharmacology 63: 1253-1264. doi: 10.1111/j.2042-7158.2011.01324.x PMID: 21899540
8. Merabishvili M, Pirnay J-P, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, et al. (2009) Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4: e4944. doi: 10.1371/journal.pone.0004944 PMID: 19300511
9. Lungren MP, Christensen D, Kankotia R, Falk I, Paxton BE, Kim CY (2013) Bacteriophage K for reduction of Staphylococcus aureus biofilm on central venous catheter material. Bacteriophage 3: e26825-26821-e26825-26825
10. O'Flaherty S, Ross RP, Meany W, Fitzgerald GF, Elbreki MF, Coffey A (2005) Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals. Applied and Environmental Microbiology 71: 1836-1842. PMID: 15812009
11. Pasternack GR, Sulakvelidze A (2010) Staphylococcus aureus: bacteriophage and uses thereof. USA: Intralytix, Inc.
12. Adams MH (1959) Bacteriophages. New York, N.Y.: Interscience Publishers.
13. Myles IA, Fontecilla NM, Valdez PA, Vithayathil PJ, Naik S, Belkaid Y, et al. (2013) Signaling via the IL-20 receptor inhibits cutaneous production of IL-1beta and IL-17A to promote infection with methicillinresistant Staphylococcus aureus. Nat Immunol 14: 804-811. doi: 10.1038/ni.2637 PMID: 23793061
14. Myles I, Pincus NB, Fontecilla NM, Datta SK (2013) Effects of parental omega-3 fatty acid intake on offspring microbiome and immunity. PLOS One 9(1): e87181.
15. Myles IA, Fontecilla NM, Janelsins BM, Vithayathil PJ, Segre JA, Datta SK (2013) Parental dietary fat intake alters offspring microbiome and immunity. J Immunol 191: 3200-3209. doi: 10.4049/jimmunol.1301057 PMID: 23935191
16. Tenover FC, Goering RV (2009) Methicillin-resistant Staphylococcus aureus strain USA:300: origin and epidemiology. Journal of Antimicrobial Chemotherapy 64: 441-446. doi: 10.1093/jac/dkp241 PMID: 19608582
17. Vandersteegen K, MattheusW, Ceyssens P-J, Bilocq F, De Vos D, Pirnay J-P, et al. (2011) Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS One 6: e24418. doi: 10.1371/journal.pone.0024418 PMID: 21931710
18. Kraushaar B, Thanh MD, Hammerl JA, Reetz J, Fetsch A, Hertwig S (2012) Isolation and characterization of phages with lytic activity against methicillin-resistant Staphylococcus aureus strains belonging to cloncal complex 398. Archives of Virology 158: 2341-2350.
19. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, et al. (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage ÖMR11. Journal of Infectious Diseases 187: 613-624. PMID: 12599078
20. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrobial Agents and Chemotherapy 51: 2765-2773. PMID: 17517843
21. Takemura-Uchiyama I, Uchiyama J, Osanai M, Morimoto N, Asagiri T, Ujihara T, et al. (2014) Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice. Microbes and Infection.
22. Chhibber S, Kaur T, Kuar S (2013) Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot Infections. PLoS One 8: e56022. doi: 10.1371/journal.pone.0056022 PMID: 23418497
23. Schlievert PM, Strandberg KL, Lin YC, Peterson ML, Leung DY (2010) Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J Allergy Clin Immunol 125: 39-49. doi: 10.1016/j.jaci.2009.10.039 PMID: 20109735
24. Holland SM (2013) Chronic granulomatous disease. Hematol Oncol Clin North Am 27: 89-99, viii. doi: 10.1016/j.hoc.2012.11.002 PMID: 23351990
25. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D (2012) Current concepts of hyperinflammation in chronic granulomatous disease. Clin Dev Immunol 2012: 252460. doi: 10.1155/2012/252460 PMID: 21808651
26. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G (2011) Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy 9: 10. doi: 10.1186/1476-7961-9-10 PMID: 21624140
27. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, et al. (2010) Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202: 1050-1058. doi: 10.1086/656043 PMID: 20726702
28. Seo MD, Kang TJ, Lee CH, Lee AY, Noh M (2012) HaCaT Keratinocytes and Primary Epidermal Keratinocytes Have Different Transcriptional Profiles of Cornified Envelope-Associated Genes to T Helper Cell Cytokines. Biomol Ther (Seoul) 20: 171-176. doi: 10.4062/biomolther.2012.20.2.171 PMID: 24116291
29. Sprenger A, Weber S, Zarai M, Engelke R, Nascimento JM, Gretzmeier C, et al. (2013) Consistency of the proteome in primary human keratinocytes with respect to gender, age, and skin localization. Mol Cell Proteomics 12: 2509-2521. doi: 10.1074/mcp.M112.025478 PMID: 23722187
30. Pastagia M, Kleinman LC, Lacerda de la Cruz EG, Jenkins SG (2012) Predicting risk for death from MRSA bacteremia. Emerg Infect Dis 18: 1072-1080. doi: 10.3201/eid1807.101371 PMID: 22709685
31. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB (2012) Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev 25: 362-386. doi: 10.1128/CMR.05022-11 PMID: 22491776
32. Hanberger H, Walther S, Leone M, Barie PS, Rello J, Lipman J, et al. (2011) Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents 38: 331-335. doi: 10.1016/j.ijantimicag.2011.05.013 PMID: 21798720
33. Rountree PM (1955) The role of divalent cations in the multiplication of staphylococcal bacteriophages. J Gen Microbiol 12: 275-287. PMID: 14367753
34. Young I, Wang I, Roof WD (2000) Phages will out: strategies of host cell lysis. Trends Microbiol 8: 120-128. PMID: 10707065
35. Blaser M, Bork P, Fraser C, Knight R, Wang J (2013) The microbiome explored: recent insights and future challenges. Nat Rev Microbiol 11: 213-217. doi: 10.1038/nrmicro2973 PMID: 23377500
36. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L (2010) Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One 5: e9836. doi: 10.1371/journal.pone.0009836 PMID: 20352091
37. Cho I, Yamanishi S, Cox L, Methe BA, Zavadil J, Li K, et al. (2012) Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488: 621-626. doi: 10.1038/nature11400 PMID: 22914093
38. Cho I, Blaser MJ (2012) The human microbiome: at the interface of health and disease. Nat Rev Genet 13: 260-270. doi: 10.1038/nrg3182 PMID: 22411464
39. Pflughoeft KJ, Versalovic J (2012) Human microbiome in health and disease. Annu Rev Pathol 7: 99-122. doi: 10.1146/annurev-pathol-011811-132421 PMID: 21910623
40. Jernberg C, Lofmark S, Edlund C, Jansson JK (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 156: 3216-3223. doi: 10.1099/mic.0.040618-0 PMID: 20705661
41. Perichon B, Courvalin P (2009) VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53: 4580-4587. doi: 10.1128/AAC.00346-09 PMID: 19506057
42. Kos VN, Desjardins CA, Griggs A, Cerqueira G, Van Tonder A, Holden MT, et al. (2012) Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States. MBio 3.
43. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, et al. (1996) Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93: 3188-3192. PMID: 8622911
44. Merril CR, Scholl D, Adhya SL (2003) The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2: 489-497. PMID: 12776223
45. Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM (2010) Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother 54: 397-404. doi: 10.1128/AAC.00669-09 PMID: 19822702
46. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, Unno H (2005) Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 100: 280-287. PMID: 16243277
47. Carvalho CM, Gannon BW, Halfhide DE, Santos SB, Hayes CM, Roe JM, et al. (2010) The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol 10: 232. doi: 10.1186/1471-2180-10-232 PMID: 20809975
48. Tanji Y, Shimada T, Yoichi M, Miyanaga K, Hori K, Unno H (2004) Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl Microbiol Biotechnol 64: 270-274. PMID: 13680205
49. Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Future Microbiol 8: 769-783. doi: 10.2217/fmb.13.47 PMID: 23701332
50. Thiel K (2004) Old dogma, new tricks - 21st Century phage therapy. Nat Biotechnol 22: 31-36. PMID: 14704699
51. Pirnay JP, Blasdel BG, Bretaudeau L, Buckling A, Chanishvili N, Clark JR, et al. (2015) Quality and Safety Requirements for Sustainable Phage Therapy Products. Pharm Res.
52. (CDC) CfDCaP (2013) Antibiotic Resistance Threats in the United States, 2013. In: Services UDoHaH, editor. Atlanta, GA.